Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical ...
Teva, Samsung Bioepis enter partnership for commercialization of EPYSQLI
Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...
The Pharma Letter2h
Samsung Bioepis and Teva link up on Soliris biosimilar in USA
South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, ...
Samsung Bioepis, Teva Enter License, Development, Commercialization Agreement For EPYSQLI
Samsung Bioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement ...
Hosted on MSN1mon
Samsung Biologics inks $668m manufacturing deal with European pharma
In July 2024, Samsung Bioepis received US Food and Drug Administration (FDA) approval for Epysqli (eculizumab-aagh), a biosimilar to AstraZeneca acquiree Alexion Pharmaceuticals’ Soliris ...
The Bakersfield Californian1d
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI®
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH),atypical hemolytic uremic syndrome (aHUS)andgeneralized myasthenia gravis (gMG)in the U ...